Key facts
- This page summarizes Thomas B. King's Form 4 filing for TFF Pharmaceuticals, Inc..
- 2 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 08 Jul 2024, 17:40.
Thomas B. King - 03 Jul 2024 Form 4 Insider Report for TFF Pharmaceuticals, Inc.
- Reporting relationship
- Director
- Issuer ticker
- N/A
- Reported as of
- 03 Jul 2024
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 08 Jul 2024, 17:40:26 UTC
- Prior SEC filing
- 22 Apr 2024
- Next SEC filing
- 14 Jan 2025
- Source filing
- View source filing
- Reporting owner signature
- /s/ Thomas B. King
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Thomas B. King filed Form 4 for TFF Pharmaceuticals, Inc. on 08 Jul 2024.
Change
- Previous filing in this sequence was filed on 22 Apr 2024.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
TFFP
transaction
Common Stock
Award
- Transaction value
- $0
- Shares
- +1,583
- Change %
- Price
- $0.000000
- Shares after
- 1,583
- Date
- 03 Jul 2024
- Ownership
- Direct
- Footnotes
- F1
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
TFFP
transaction
Derivative
Stock Options (Right to Buy)
Award
- Transaction value
- $0
- Shares
- +1,583
- Change %
- Price
- $0.000000
- Shares after
- 1,583
- Date
- 03 Jul 2024
- Ownership
- Direct
- Underlying class
- Common stock
- Underlying amount
- 1,583
- Exercise price
- $1.82
- Footnotes
- F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
Represents shares of common stock underlying restricted stock units ("RSUs"). Each RSU entitles its holder to receive one share of common stock of the issuer. The RSUs vest and settle in full on June 19, 2025.
Footnote F2
Options vest in full on June 19, 2025.